ERCCI AND RRMI GENES AS PREDICTIVE BIOMARKERS IN NON-SMALL CELL LUNG CANCER

Julija Fadejeva1, 2, Dovilė Šiuškaitė1, Saulius Cicėnas2, Diana Schveigert2

1 Faculty of Natural Sciences, Vilnius University, Vilnius, Lithuania

2 National Cancer Institute, Vilnius, Lithuania

INTRODUCTION. Lung cancer is one of the most common oncological diseases and the leading causes of cancer-related deaths worldwide. Platinum-based chemotherapy drugs are used for non-small cell lung cancer (NSCLC) patients' treatment. However, drug resistance in cancer chemotherapy is a major problem that is observed nowadays [1]. Still, there are no reliable molecular biomarkers to predict whether a tumor responds to platinum-based chemotherapy. Potential predictive biomarkers could be ERCCI and RRMI genes which are involved in nucleotide excision repair system.

AIM. The aim of this study was to identify association between ERCCI and RRM1 gene expression and NSCLC patients' response to treatment.

MATERIALS AND METHODS. The study included 80 NSCLC patients treated at Department of Thoracic Surgery and Oncology, National Cancer Institute (Vilnius, Lithuania). Blood samples of the patients were analyzed before and after treatment. RNA was extracted from whole blood using „QIAamp RNA Blood Mini Kit“ (QIAGEN, Germany). The analysis of ERCC1 and RRM1 expression was done by qRT-PCR method. Each sample was examined in triplicate. Changes in ERCC1 and RRM1 expression were calculated using $2^{-\Delta\Delta CT}$ method. Patients were separated into those with low and high gene expression. The statistical analysis was done by IBM SPSS 21 (Armonk, NY: IBM Corp, JAV, 2012) software. A $\chi^2$ test was used to analyze ERCCI and RRM1 in relation to patients' clinical-pathological parameters and response to treatment. Results were considered as statistically significant when p$\le$0,05. The present study was approved by the Lithuanian Bioethics Committee.

RESULTS. Statistically significant differences were found between ERCCI expression in patients' blood before treatment and patients' gender. High ERCCI expression was identified more often among men (p=0,044). Moreover, there are trends in the association between ERCCI expression after treatment, tumor differentiation grade and response to treatment. High ERCCI expression is more common for poor differentiation tumors and stable disease (respectively, p=0,066 and p=0,051). Similarly, there are trends in the association between RRM1 expression in blood and patients' response to treatment. High RRM1 expression after treatment was identified more often among NSCLC patients with stable disease (p=0,051).

CONCLUSIONS. ERCCI and RRM1 genes may influence platinum-based chemotherapy treatment of NSCLC patients. In order to improve the effectiveness of treatment it is appropriate to identify ERCCI expression changes in the blood. Therefore, NSCLC patients with low RRM1 expression should be actively followed-up because of quicker disease progression. For the prediction of clinical outcome of NSCLC patients additional studies with larger population group should be done in the future.


[1] S. Sun, W. Shi, Z. Wu, G. Zhang, B.O. Yang, S. Jiao. Prognostic significance of the mRNA expression of ERCC1, RRM1, TUBB3 and TYMS genes in patients with non-small cell lung cancer, Experimental and Therapeutic Medicine 10 (3), 937-941 (2015).